Vanguard Group Inc. Boosts Stock Position in Recursion Pharmaceuticals, Inc. $RXRX

Vanguard Group Inc. boosted its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 18.6% during the 4th quarter, Holdings Channel.com reports. The firm owned 47,187,759 shares of the company’s stock after purchasing an additional 7,407,606 shares during the quarter. Vanguard Group Inc. owned approximately 0.09% of Recursion Pharmaceuticals worth $192,998,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Xponance Inc. increased its holdings in Recursion Pharmaceuticals by 8.0% during the 3rd quarter. Xponance Inc. now owns 30,020 shares of the company’s stock worth $146,000 after purchasing an additional 2,221 shares during the last quarter. NewEdge Advisors LLC increased its holdings in shares of Recursion Pharmaceuticals by 28.1% in the 2nd quarter. NewEdge Advisors LLC now owns 11,061 shares of the company’s stock valued at $56,000 after acquiring an additional 2,428 shares during the last quarter. Equitable Holdings Inc. increased its holdings in shares of Recursion Pharmaceuticals by 7.1% in the 3rd quarter. Equitable Holdings Inc. now owns 39,400 shares of the company’s stock valued at $192,000 after acquiring an additional 2,600 shares during the last quarter. Cherry Creek Investment Advisors Inc. increased its holdings in shares of Recursion Pharmaceuticals by 4.1% in the 3rd quarter. Cherry Creek Investment Advisors Inc. now owns 66,781 shares of the company’s stock valued at $326,000 after acquiring an additional 2,649 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in shares of Recursion Pharmaceuticals by 1.2% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 232,370 shares of the company’s stock valued at $954,000 after acquiring an additional 2,753 shares during the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Recursion Pharmaceuticals

In related news, CEO Najat Khan sold 28,298 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $3.35, for a total transaction of $94,798.30. Following the completion of the transaction, the chief executive officer owned 2,262,085 shares in the company, valued at $7,577,984.75. The trade was a 1.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Blake Borgeson sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $3.52, for a total value of $105,600.00. Following the transaction, the director owned 6,199,863 shares of the company’s stock, valued at $21,823,517.76. This represents a 0.48% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 109,680 shares of company stock worth $361,721 in the last 90 days. 8.43% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Bank of America lowered their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating for the company in a report on Wednesday, February 25th. Wall Street Zen downgraded Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. JPMorgan Chase & Co. lowered their price target on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a report on Thursday, April 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Tuesday, April 21st. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Recursion Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $9.20.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ RXRX opened at $3.32 on Monday. Recursion Pharmaceuticals, Inc. has a twelve month low of $2.80 and a twelve month high of $7.18. The company has a market capitalization of $1.76 billion, a price-to-earnings ratio of -2.77 and a beta of 1.05. The company has a current ratio of 5.47, a quick ratio of 5.47 and a debt-to-equity ratio of 0.01. The business has a 50 day simple moving average of $3.40 and a 200-day simple moving average of $4.12.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.The business had revenue of $6.47 million during the quarter, compared to analyst estimates of $15.78 million. During the same quarter in the previous year, the firm posted ($0.50) EPS. The business’s revenue for the quarter was down 56.8% compared to the same quarter last year. As a group, equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.07 earnings per share for the current year.

Key Recursion Pharmaceuticals News

Here are the key news stories impacting Recursion Pharmaceuticals this week:

• Positive Sentiment: Recursion highlighted multiple clinical progress points across its AI-enabled pipeline, including positive early data for REC-1245, a new Phase 1 trial for REC-4539, and Phase 2 success for REC-4881 in familial adenomatous polyposis, with FDA discussions underway for a potential registrational path. Article Title
• Positive Sentiment: The company reported a narrower-than-expected Q1 loss, beating analyst EPS estimates, which supports the view that operating results are improving even though the business remains unprofitable. Article Title
• Neutral Sentiment: Needham reaffirmed a Buy rating and set an $8.00 price target, reinforcing a bullish long-term view from one analyst. Article Title
• Neutral Sentiment: Bank of America reiterated a Hold rating, reflecting a more cautious stance and limiting enthusiasm around the stock. Article Title
• Negative Sentiment: Despite the better EPS result, quarterly revenue fell sharply year over year and came in well below expectations, showing that Recursion still faces meaningful commercialization and collaboration revenue headwinds. Article Title
• Negative Sentiment: A director sold 30,000 shares under a pre-arranged 10b5-1 plan, which can add to investor caution even though the sale was routine and relatively small versus his remaining stake. Article Title

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.